July 03, 2017
1 min read

FDA accepts application for proposed biosimilar to Rituxan

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The FDA has accepted a biologics license application for Celltrion Inc. and Teva’s CT-P10, a proposed biosimilar to Rituxan, for the treatment of rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis, chronic lymphocytic leukemia and non-Hodgkin’s lymphoma, according to a company press release.

“As the global leader in biosimilars who brought Inflectra, the world’s first [monoclonal antibody] mAb biosimilar approved by the FDA, to the U.S., we are pleased and honored to have this opportunity to once again work with the FDA on CT-P10,” Woo Sung Kee, chief executive officer of Celltrion, said in the release. “CT-P10, which has been approved in the [European Union] E.U., is continuing to build a solid track record since its launch there earlier this year and has provided patients with access to a high-quality treatment option and has offered great savings in health care costs. I am hopeful that CT-P10 will bring similar benefits to the [United States] U.S. when approved.”

The application for CT-P10 included data from more than 600 patients and 104 weeks. According to the release, FDA regulatory action is expected in the first quarter of 2018.